RLAY

Relay Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26

Figures on this page computed 2026-11-08 12:48 UTC

Last close

18.03USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-02-26

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-076739
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-26
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-076739
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-06
The filing itself
-1800.6%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-076739
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
-1536.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-076739
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
0.06Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-076739
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-06
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Price is the furthest below its sector's middle: 0.10 against 0.38 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.67x

1.24x

1.42x

1.24x

1.00x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-26

Sales0.67x
Its own average over 6 years, 23.0M.
Profit1.24x
Its own average over 8 years, -223.4M.
Free cash flow1.42x
Its own average over 8 years, -166.5M.
Debt1.24x
Its own average over 5 years, 26.1M.
Price1.00x
Its own average over 7 years, 18. Market data, 2026-11-04

Free cash flow is furthest from its own average, at 1.42 times.

Sales is 0.67 times its own 6-year average; Profit is 1.24 times its own 8-year average; Free cash flow is 1.42 times its own 8-year average; Debt is 1.24 times its own 5-year average; Price is 1.00 times its own 7-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-26

Sales against its own 6-year average0.67
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-076739
Reported in
USD
The filing itself
Profit against its own 8-year average1.24
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-076739
Reported in
USD
The filing itself
Free cash flow against its own 8-year average1.42
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-076739
Reported in
USD
The filing itself
Debt against its own 5-year average1.24
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-076739
Reported in
USD
The filing itself
Price against its own 7-year average1.00Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD